Eric Joseph
Stock Analyst at JP Morgan
(2.07)
# 3,013
Out of 5,113 analysts
124
Total ratings
40.48%
Success rate
-4.87%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $4.47 | +146.09% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $30.31 | +61.66% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $29.02 | +58.51% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $71.16 | -10.06% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.58 | +95.53% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $4.03 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $9.23 | -24.16% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $75.60 | -11.38% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.28 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.25 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $17.87 | +67.88% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $7.57 | +84.94% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $97.33 | -27.05% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $23.66 | +60.61% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.00 | +475.00% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $12.73 | +33.54% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $7.65 | +174.51% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $12.65 | -20.95% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.26 | +1,090.48% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.03 | +195.57% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $21.13 | -47.94% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $24.03 | +316.15% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.36 | +111.86% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.87 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $34.26 | -67.89% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $21.69 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $6.92 | +1,634.10% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $8.06 | +3,622.08% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.81 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.45 | +520.69% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.45 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.57 | +1,534.24% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $4.79 | +171.40% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.36 | +2,922.81% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $4.47
Upside: +146.09%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $30.31
Upside: +61.66%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $29.02
Upside: +58.51%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $71.16
Upside: -10.06%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.58
Upside: +95.53%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.03
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $9.23
Upside: -24.16%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $75.60
Upside: -11.38%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $17.87
Upside: +67.88%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $7.57
Upside: +84.94%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $97.33
Upside: -27.05%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $23.66
Upside: +60.61%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $4.00
Upside: +475.00%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $12.73
Upside: +33.54%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $7.65
Upside: +174.51%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $12.65
Upside: -20.95%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.26
Upside: +1,090.48%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.03
Upside: +195.57%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $21.13
Upside: -47.94%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $24.03
Upside: +316.15%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.36
Upside: +111.86%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.87
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $34.26
Upside: -67.89%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $21.69
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $6.92
Upside: +1,634.10%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $8.06
Upside: +3,622.08%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $11.81
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.45
Upside: +520.69%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.45
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.57
Upside: +1,534.24%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $4.79
Upside: +171.40%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.36
Upside: +2,922.81%